Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher to Provide £5M Loan to Premaitha Health as Firm's H1 2016 Revenues Climb

NEW YORK (GenomeWeb) – Premaitha Health said today that it has signed an agreement under which Thermo Fisher Scientific will provide it with a £5 million ($7.6 million) loan. The UK-based noninvasive prenatal test provider also reported £0.6 million in revenues for the first half of its fiscal year 2016 today.

Thermo Fisher will invest £5 million in Premaitha as a secured loan facility, of which the company will receive £3 million initially and the remainder as milestone payments over the next two years.

The loan is repayable between Dec. 14, 2022 and Dec. 14, 2023. Interest, which will accrue at 6 percent per year, is payable quarterly in arrears or can be converted into loan principal.

In return, Premaitha will issue warrants for 20,325,204 new ordinary shares to Thermo Fisher at an exercise price of 24.6 pence per share, representing 8.2 percent of the firm's issued share capital, or 7.1 percent on a fully diluted basis. These warrants will expire after eight years.

"This investment will enable us to expand our global reach, [and] support our marketing and clinical and technical capabilities. It will also provide future product development opportunities in the rapidly growing noninvasive prenatal testing market," Premaitha CEO Stephen Little said in a statement.

The company's CE-marked Iona NIPT uses Thermo Fisher's Ion Proton sequencer and Ion Chef sample prep instrument.

Premaitha also reported earnings today for the first half of its fiscal year 2016, which ended Sept. 30. The company booked £600,000 in revenues from the Iona test, which it launched in February, up from £100,000 during the same period last year.

The company had a loss before one-off and non-cash items of £2.7 million, up from £2.3 million during the first half of fiscal 2014, reflecting staff recruitment, product development, and commercialization activities.

In July, the firm raised £8 million, at 20 pence per share, through an oversubscribed placement.

During the first half of FY 2016, Premaitha also increased its provision for anticipated litigation costs to £1.9 million to defend itself against patent infringement claims from Illumina.

"We continue to enhance the [Iona] test for laboratory efficiency and include clinically relevant features such as the recently added fetal sex determination option," Little said in a statement. "We remain on course for our target of 10 contract wins this financial year, despite the unpredictable timing inherent in such a complex sales process and the distraction of a non-CE marked competitor's litigation."

During the first half of 2016, the company installed the Iona test in four laboratories in the UK, Switzerland, and Poland.

As of Sept. 30, Premaitha had £6.6 million in cash reserves.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more